The combination therapy of oncolytic HSV-1 armed with anti-PD-1 antibody and IL-12 enhances anti-tumor efficacy

The combination therapy of oncolytic HSV-1 armed with anti-PD-1 antibody and IL-12 enhances anti-tumor efficacy

Cancer immunotherapy is a new therapeutic strategy for cancer treatment that targets tumors by improving or restoring immune system function. Therapies targeting immune checkpoint molecules have exerted potent anti-tumor effects and prolonged the overall survival rate of patients. However, only a sm...

Full description

Bibliographic Details
Main Authors: Xin Xie, Jingwen Lv, Wei Zhu, Chao Tian, Jingfeng Li, Jiajia Liu, Hua Zhou, Chunyang Sun, Zongfeng Hu, Xiaopeng Li
Format: Article
Language:English
Published: Elsevier 2022-01-01
Series:Translational Oncology
Subjects:
Oncolytic virus
HSV-1
IL-12
PD-1 antibody
Cancer immunotherapy
Online Access:http://www.sciencedirect.com/science/article/pii/S1936523321002783

Internet

http://www.sciencedirect.com/science/article/pii/S1936523321002783

Similar Items